715
THE EFFECT OF GUT MICROBIOTA ON IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF PAN-CANCER AND NOVEL MICROBIAL BIOMARKERS FOR PREDICTING THERAPEUTIC RESPONSE
Date
May 20, 2024
Tracks
Related Products
FAECALIBACTERIUM PRAUSNITZII INHIBITS GASTRIC CANCER AND ANTAGONIZES HELICOBACTER PYLORI COLONIZATION
BACKGROUND: The roles of probiotics in inhibiting gastric cancer (GC) and effecting _H. pylori_ infection are largely unclear. We identified _Faecalibacterium prausnitzii_ is depleted in GC. We aimed to evaluate the antitumorigenic function and molecular mechanism of _F…
<i>LACTOBACILLUS ACIDOPHILUS </i>SUPPRESSES NON-ALCOHOLIC FATTY LIVER DISEASE-ASSOCIATED HEPATOCELLULAR CARCINOMA THROUGH PRODUCING METABOLITE VALERIC ACID
BACKGROUND: Through shotgun metagenomic sequencing, we identified the depletion of probiotic species_ Lactobacillus acidophilus_ in stools of mice with non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC)…
ACETATE-PRODUCING BIFIDOBACTERIUM CATENULATUM BOOSTS ANTI-PD1 EFFICACY IN COLORECTAL CANCER VIA ACTIVATION OF CYTOTOXIC CD8+ CELLS
BACKGROUND: _Bifidobacterium catenulatum_ was reported to attenuate inflammation through modulating gut microbiota. Here, we investigated the roles of _B…
<i>LACTOCOCCUS LACTIS </i>SUPPRESSES COLORECTAL TUMORIGENESIS BY RESTORING GUT MICROBIOME COMPOSITION AND GENERATING BENEFICIAL ALPHA- MANNOSIDASE
BACKGROUND: Through shotgun metagenomic sequencing, we identified the depletion of probiotic species_ Lactobacillus acidophilus_ in stools of mice with non-alcoholic fatty liver disease-associated hepatocellular carcinoma (NAFLD-HCC)…